Methods and compositions for treating hepatitis C virus
View Patent ↗A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
1. A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount β-D nucleoside compound of the structure:
or a pharmaceutically acceptable salt or ester thereof.
2. A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
or a pharmaceutically acceptable salt or ester thereof.
3. A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
or a pharmaceutically acceptable salt or ester thereof.
4. A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
or a pharmaceutically acceptable thereof, optionally in a pharmaceutically acceptable carrier.
5. A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier or diluent.
6. A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier or diluent.
7. A method for treatment of a Hepatitis C virus infection in a host in need thereof, comprising administering to said host an antivirally effective amount of a β-D nucleoside compound of the structure:
or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.
8. A method for treatment of a Hepatitis C virus infection in a host in need thereof, comprising administering to said host an antivirally effective amount of a β-D nucleoside compound of the structure:
or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.
9. A method for treatment of a Hepatitis C virus infection in a host in need thereof, comprising administering to said host an antivirally effective amount of a β-D nucleoside compound of the structure:
or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.
10. The method of any one claims 7 , 8 , 9 , or 1 - 6 , wherein the pharmaceutically acceptable carrier is suitable for oral delivery.
11. The method of any one claims 7 , 8 , 9 , or 1 - 6 , wherein the pharmaceutically acceptable carrier is suitable for intravenous delivery.
12. The method of any one claims 7 , 8 , 9 , or 1 - 6 , wherein the pharmaceutically acceptable carrier is suitable for parental delivery.
13. The method of any one claims 7 , 8 , 9 , or 1 - 6 , wherein the pharmaceutically acceptable carrier is suitable for intradermal delivery.
14. The method of any one claims 7 , 8 , 9 , or 1 - 6 , wherein the pharmaceutically acceptable carrier is suitable for subcutaneous delivery.
15. The method of any one claims 7 , 8 , 9 , or 1 - 6 , wherein the pharmaceutically acceptable carrier is suitable for topical delivery.
16. The method of any one claims 7 , 8 , 9 , or 1 - 6 , wherein the compound is in the form of a dosage unit, such that said dosage unit contains 10 to 1500 mg of the compound.
17. The method of any one claims 7 , 8 , 9 , or 1 - 6 , wherein the compound is in the form of a dosage unit that is a tablet or capsule.
18. The method of any one claims 7 , 8 , or 9 , wherein the host is a human.
19. The method of any one of claims 7 - 9 or 1 - 6 , wherein the compound is at least 90% by weight free of the β-L-isomer.
20. The method of any one of claims 7 - 9 or 1 - 6 , wherein the compound is at least 95% by weight free of the β-L-isomer.
21. The method of any one of claims 7 - 9 or 1 - 6 , wherein the compound is at least 85% by weight free of the β-L-isomer.
22. A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
23. A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
24. A method for treatment of a Hepatitis C virus infection in a human in need thereof, comprising administering to said human an antivirally effective amount of a β-D nucleoside compound of the structure:
25. A method for treatment of a Hepatitis C virus infection in a host in need thereof, comprising administering to said host an antivirally effective amount of a β-D-2′-C-branded pyrimidine nucleoside.
26. A method for treatment of a Hepatitis C virus infection in a host in need thereof, comprising administering to said host an antivirally effective amount of a β-D-2′-C-branded pyrimidine nucleoside.
27. A method of any one claims 25 - 26 , wherein the host is a human.